Applied DNA Sciences Yönetim

Yönetim kriter kontrolleri 4/4

Applied DNA Sciences CEO'su James Hayward, Mar2006 tarihinde atandı, in görev süresi 18.67 yıldır. in toplam yıllık tazminatı $ 468.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 96.2% maaş ve 3.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.021% ine doğrudan sahiptir ve bu hisseler $ 1.72K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 9.8 yıl ve 8.8 yıldır.

Anahtar bilgiler

James Hayward

İcra Kurulu Başkanı

US$468.0k

Toplam tazminat

CEO maaş yüzdesi	96.2%
CEO görev süresi	18.7yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	9.8yrs
Yönetim Kurulu ortalama görev süresi	8.8yrs

Son yönetim güncellemeleri

Recent updates

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Dec 20

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Aug 17

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise

Aug 09

CEO Tazminat Analizi

James Hayward'un ücretlendirmesi Applied DNA Sciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	n/a	n/a	-US$7m
Sep 30 2023	US$468k	US$450k	-US$10m
Jun 30 2023	n/a	n/a	-US$7m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	n/a	n/a	-US$7m
Sep 30 2022	US$2m	US$450k	-US$8m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	n/a	n/a	-US$14m
Sep 30 2021	US$1m	US$400k	-US$14m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	n/a	n/a	-US$15m
Sep 30 2020	US$451k	US$133k	-US$13m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	n/a	n/a	-US$8m
Sep 30 2019	US$375k	US$233k	-US$9m
Jun 30 2019	n/a	n/a	-US$11m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	n/a	n/a	-US$12m
Sep 30 2018	US$481k	US$250k	-US$12m

Tazminat ve Piyasa: James 'ın toplam tazminatı ($USD 468.00K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 650.80K ).

Tazminat ve Kazançlar: James 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

James Hayward (70 yo)

18.7yrs

Görev süresi

US$468,000

Tazminat

Dr. James A. Hayward, Ph D., Sc D., has been Chief Executive Officer and Chairman of Applied DNA Sciences, Inc. (Formerly Known as Prohealth Medical Tech, Inc) since March 17, 2006 and June 12, 2007, respe...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Hayward	Chairman	18.7yrs	US$468.00k	0.021% $ 1.7k
Beth Jantzen	Chief Financial Officer	9.8yrs	US$501.00k	0.0066% $ 524.2
Judith Murrah	COO, Chief Information Officer & Secretary	11.4yrs	US$542.75k	0.0075% $ 597.7
Clay Shorrock	Chief Legal Officer & Executive Director of Business Development	3.6yrs	US$501.00k	0.0090% $ 716.0
Sanjay Hurry	Executive Director of Investor Relations & Corporate Communications	4.3yrs	Veri yok	Veri yok

9.8yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: APDN 'un yönetim ekibi deneyimli ve deneyimlidir ( 9.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Hayward	Chairman	19.2yrs	US$468.00k	0.021% $ 1.7k
Robert Catell	Chairman of Strategic Advisory Board & Independent Director	8.8yrs	US$152.50k	0.00031% $ 24.8
Yacov Shamash	Independent Director	18.7yrs	US$162.50k	0.00025% $ 20.0
Raymond Kelly	Member of Strategic Advisory Board	7.8yrs	Veri yok	Veri yok
Joseph Ceccoli	Independent Director	9.9yrs	US$155.00k	0.000090% $ 7.2
Sanford Simon	Independent Director	18.7yrs	US$151.25k	0.000010% $ 0.8
Mehmood Khan	Member of Strategic Advisory Board	8.1yrs	Veri yok	Veri yok
Gunther Faber	Member of Strategic Advisory Board	8.8yrs	Veri yok	Veri yok
Elizabeth M. Shaheen	Independent Director	7.4yrs	US$153.75k	0.00012% $ 9.6
Stephen Birkhold	Member of Strategic Advisory Board	5.8yrs	Veri yok	Veri yok

8.8yrs

Ortalama Görev Süresi

73.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: APDN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.8 yıldır).

Applied DNA Sciences Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Applied DNA Sciences, Inc., Annual General Meeting, Sep 30, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

Insufficient new directors

Recent updates

Applied DNA Sciences, Inc. Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Applied DNA Sciences, Inc. announced that it has received funding

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.499893 million.

New major risk - Market cap size

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc.'s Applied DNA Clinical Labs, LLC Launches Mpox Clade I and Clade II Testing Service

Applied DNA Sciences, Inc. to Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Consensus revenue estimates fall by 20%

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Applied DNA Sciences, Inc. to Report Q3, 2024 Results on Aug 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Sep 30, 2024

Applied DNA Sciences Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$5.32 loss

Applied DNA Sciences, Inc. Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million.

New major risk - Share price stability

New major risk - Financial position

New major risk - Shareholder dilution

Consensus estimates of losses per share improve by 24%

Applied DNA Sciences, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering.

Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress

Consensus EPS estimates upgraded to US$0.65 loss, revenue downgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Applied DNA Sciences, Inc. to Report Q1, 2024 Results on Feb 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.436992 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.437233 million.

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Consensus revenue estimates fall by 49%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Applied DNA Sciences Receives Non-Compliance Notice From Nasdaq

Applied DNA Sciences, Inc. to Report Q4, 2023 Results on Dec 07, 2023

Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna)

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Applied DNA Sciences, Inc. to Report Q3, 2023 Results on Aug 10, 2023

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

New minor risk - Share price stability

Applied DNA Sciences, Inc. (NasdaqCM:APDN) acquired Spindle Biotech Inc. for $2.8 million.

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences, Inc. to Report Q2, 2023 Results on May 11, 2023

Consensus revenue estimates increase by 12%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Applied DNA Sciences, Inc. to Report Q1, 2023 Results on Feb 09, 2023

Applied DNA Sciences, Inc. Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA as New Class of DNA-Based Vaccines

Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 20%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to US$7.00

Applied DNA Sciences, Inc. to Report Q4, 2022 Results on Dec 05, 2022

Applied DNA climbs 51% after winning large purchase order

Applied DNA Sciences, Inc.'s Subsidiary, Applied DNA Clinical Labs, LLC, Launches Monkeypox Testing Service

Applied DNA stock rises 12% on launching monkeypox testing service in New York

Applied DNA Submits PCR-Based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Applied DNA adds 17% as company seeks approval for monkeypox test in New York

Consensus estimates of losses per share improve by 19%

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise